Episodes

  • Longevity Biotechnology: AI, Biomarkers, Geroscience & Applications for Healthy Aging

    Longevity Biotechnology: AI, Biomarkers, Geroscience & Applications for Healthy Aging
    Oct 31 2024
    BUFFALO, NY- October 31, 2024 – A new #research paper was #published as the #cover of Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science), Volume 16, Issue 20, entitled, “Longevity biotechnology: bridging AI, biomarkers, geroscience and clinical applications for healthy longevity.” This paper summarizes recent advances in healthspan biotechnology discussed at the 2023 Aging Research and Drug Discovery Meeting (ARDD), where leading experts reviewed breakthroughs in artificial intelligence (AI), biomarkers, aging clocks, geroscience, and clinical trials that support healthier, longer lives. The authors present a comprehensive view of how these technologies are shaping research and industry approaches to aging, focusing on targeting aging itself to reduce multiple age-related diseases and extend the healthy years of life. With people living longer, addressing age-related health issues is more critical than ever. Traditional healthcare often treats age-related diseases individually, overlooking aging as a core issue. Longevity biotechnology seeks to change this by combining AI with biomarker analysis to detect early signs of aging, enabling targeted interventions that not only delay disease but also promote longer, healthier lives. Led by corresponding authors Yu-Xuan Lyu from Southern University of Science and Technology Shenzhen; Alex Zhavoronkov from Insilico Medicine AI Limited, Masdar City, Abu Dhabi; Morten Scheibye-Knudsen and Daniela Bakula from the Center for Healthy Aging, University of Copenhagen, this research synthesizes the potential of AI to identify precise biomarkers of aging, supporting the development of "aging clocks"—tools that use biological data to estimate a person’s biological age and health risks. These tools help clinicians tailor prevention and treatment to individual needs. Additionally, AI speeds up the discovery of drugs that target primary aging drivers, such as cellular damage and decreased cellular energy, offering the potential to slow, prevent, or even reverse certain effects of aging and enhance quality of life. “The fusion of AI with biomarker research has markedly revolutionized the way biomarkers are identified and validated in the field of ageing.” This approach not only promises to slow, prevent, or even reverse certain effects of aging but also emphasizes the potential for AI-driven methods to extend healthspans. In conclusion, the authors emphasize the need for continued investment in AI-driven therapies and biomarker research, which hold the potential to redefine aging care and improve health outcomes as people grow older. DOI - https://doi.org/10.18632/aging.206135 Corresponding Authors - Yu-Xuan Lyu - lvyx@sustech.edu.cn, Alex Zhavoronkov - alex@insilico.com, Morten Scheibye-Knudsen - mscheibye@sund.ku.dk, and Daniela Bakula - bakula@sund.ku.dk Video short - https://www.youtube.com/watch?v=Hpfe5WJ5g7I Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206135 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, biotechnology, artificial intelligence, healthy longevity About Aging-US The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.) Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM
    Show More Show Less
    4 mins
  • Cardiovascular Risk Biomarkers in Inflammaging

    Cardiovascular Risk Biomarkers in Inflammaging
    Oct 29 2024
    BUFFALO, NY- October 29, 2024 – A new #editorial was #published in Aging (listed by MEDLINE/PubMed as “Aging (Albany NY)” and “Aging-US” by Web of Science) Volume 16, Issue 19 on October 14, 2024, entitled “Integrating cardiovascular risk biomarkers in the context of inflammaging.” Cardiovascular diseases (CVD) remain the leading cause of death worldwide, accounting for nearly one-third of all global mortalities. Risk assessment for CVD has traditionally focused on well-known factors linked to atherosclerosis, including demographics, lifestyle choices like smoking and physical activity, and conditions such as diabetes, hypertension, and obesity. Biomarkers, such as non-HDL cholesterol, have also played a key role in identifying those at risk. However, significant residual cardiovascular risk persists despite managing these established risk factors, suggesting additional, unaddressed contributors to cardiovascular health. In their paper, researchers Jacopo Sabbatinelli, Matilde Sbriscia, Fabiola Olivieri, and Angelica Giuliani from Università Politecnica delle Marche and IRCCS INRCA in Ancona, Italy, explore how integrating specific cardiovascular biomarkers could help assess this residual inflammatory risk, particularly in the context of aging-related inflammation, or “inflammaging.” The biomarkers investigated—high-sensitivity C-reactive protein (hs-CRP), high-sensitivity cardiac troponin (hs-cTn), and natriuretic peptides—serve as valuable indicators of both inflammatory burden and early cardiovascular risk. In conclusion, the authors demonstrate that combining markers of chronic inflammation with cardiac health indicators offers a more complete understanding of cardiovascular risk and reveals the impact of aging-related inflammation, or “inflammaging,” on heart health. Researchers suggest that this approach opens new avenues for targeted interventions in aging populations. DOI - https://doi.org/10.18632/aging.206136 Corresponding author - Jacopo Sabbatinelli - j.sabbatinelli@staff.univpm.it Video short - https://www.youtube.com/watch?v=yJJXbwHj6hs Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206136 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, cardiovascular disease, inflammaging, cardiac biomarkers, residual inflammatory risk About Aging-US The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population. The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.) Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM
    Show More Show Less
    4 mins
  • New Model to Study Macrophage Aging Mechanisms

    New Model to Study Macrophage Aging Mechanisms
    Oct 24 2024
    BUFFALO, NY- October 24, 2024 – A new #research paper was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science), Volume 16, Issue 19 on October 3, 2024, entitled “A new model and precious tool to study molecular mechanisms of macrophage aging.” As highlighted in the abstract, the accumulation of senescent cells, marked by a senescence-associated secretory phenotype (SASP), plays a role in chronic inflammation and age-related diseases (ARD). During aging, macrophages can develop a senescent-like phenotype with altered functions, promoting the buildup of senescent cells. In the context of aging and ARD, controlling the resolution of inflammation and preventing chronic inflammation—particularly by targeting macrophages—should be a priority. In their paper, researchers Rémy Smith, Kévin Bassand, Ashok Dussol, Christophe Piesse, Eric Duplus, and Khadija El Hadri from Sorbonne Université in Paris and Université Sorbonne Paris Nord in Bobigny, France, developed an in vitro model of murine peritoneal macrophage aging. Using this model, they demonstrated that chronic treatment with CB3, a thioredoxin-1 mimetic anti-inflammatory peptide, completely prevents the increase of p21CIP1 and allows day 14 macrophages to maintain their proliferative activity. "We describe a new model of macrophage aging with a senescence-like phenotype associated with inflammatory, metabolic and functional perturbations.” DOI - https://doi.org/10.18632/aging.206124 Corresponding authors - Eric Duplus - eric.duplus@sorbonne-universite.fr, and Khadija El Hadri - khadija.zegouagh@sorbonne-universite.fr Video short - https://www.youtube.com/watch?v=LfN78LR-CYU Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206124 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, macrophage, inflammation, senescence, thioredoxin-1 mimetic peptide About Aging-US The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population. The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.) Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM
    Show More Show Less
    3 mins
  • Longevity & Aging Series (S2, E3): Dr. Jon Berner

    Longevity & Aging Series (S2, E3): Dr. Jon Berner
    Oct 23 2024
    In this installment of the Longevity & Aging Series, Dr. Jon Berner from the Woodinville Psychiatric Associates in Woodinville, WA, joined host Dr. Evgeniy Galimov to discuss a research paper he co-authored that was published in Volume 16, Issue 14 of Aging (Aging-US), entitled, “mTORC1 activation in presumed classical monocytes: observed correlation with human size variation and neuropsychiatric disease.” DOI - https://doi.org/10.18632/aging.206033 Corresponding author - Jon Berner - jonbernermd@gmail.com Video interview - https://www.youtube.com/watch?v=45L89MaJ7qA Abstract Background: Gain of function disturbances in nutrient sensing are likely the largest component in human age-related disease. Mammalian target of rapamycin complex 1 (mTORC1) activity affects health span and longevity. The drugs ketamine and rapamycin are effective against chronic pain and depression, and both affect mTORC1 activity. Our objective was to measure phosphorylated p70S6K, a marker for mTORC1 activity, in individuals with psychiatric disease to determine whether phosphorylated p70S6K could predict medication response. Methods: Twenty-seven females provided blood samples in which p70S6K and phosphorylated p70S6K were analyzed. Chart review gathered biometric measurements, clinical phenotypes, and medication response. Questionnaires assessed anxiety, depression, autism traits, and mitochondrial dysfunction, to determine neuropsychiatric disease profiles. Univariate and multivariate statistical analyses were used to identify predictors of medication response. Results: mTORC1 activity correlated highly with both classical biometrics (height, macrocephaly, pupil distance) and specific neuropsychiatric disease profiles (anxiety and autism). Across all cases, phosphorylated p70S6K was the best predictor for ketamine response, and also the best predictor for rapamycin response in a single instance. Conclusions: The data illustrate the importance of mTORC1 activity in both observable body structure and medication response. This report suggests that a simple assay may allow cost-effective prediction of medication response. Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206033 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, ketamine, lithium, monocyte, mTORC1, rapamycin About Aging-US The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population. The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.) Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM
    Show More Show Less
    37 mins
  • Tribute to Dr. Mikhail (Misha) Blagosklonny

    Tribute to Dr. Mikhail (Misha) Blagosklonny
    Oct 22 2024
    It is with great sadness and heavy heart that we announce the recent passing of Dr. Mikhail (Misha) V. Blagosklonny, our beloved Editor-in-Chief. Misha succumbed to metastatic lung cancer after a courageous battle. Dr. Blagosklonny will be remembered as a brilliant and extraordinary scientist who dedicated his life to science. He was a visionary thinker, who made highly original contributions to cancer and aging research that were often ahead of their time. Dr. Blagosklonny was born into a family of scientists. His mother, Professor of Medicine Yanina V. Blagosklonnaya, specialized in endocrinology and was a talented teacher, mentoring several generations of medical students. His father, Professor Vladimir M. Dilman, was a brilliant gerontologist, endocrinologist and oncologist, known for being a very charismatic person. He was the first person to encourage Misha to think about nature, aging, and philosophy. Misha was a theorist by nature. While in school, he was deeply interested in physics and dreamed of becoming a theoretical physicist. Eventually, he chose biology, driven to study aging and age-related diseases, including cancer. He started as an experimentalist, but over the years, he became a theoretical biologist. In a way, his dream came true. The full tribute to Misha - https://www.aging-us.com/news-room/tribute-to-dr-mikhail-misha-blagosklonny
    Show More Show Less
    13 mins
  • Senolytics Dasatinib and Quercetin for Prevention of Pelvic Organ Prolapse in Mice

    Senolytics Dasatinib and Quercetin for Prevention of Pelvic Organ Prolapse in Mice
    Oct 22 2024
    BUFFALO, NY- October 22, 2024 – A new #research paper was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science), Volume 16, Issue 19 on September 26, 2024, entitled, “Use of the senolytics dasatinib and quercetin for prevention of pelvic organ prolapse in a mouse animal model.” Pelvic organ prolapse is a common condition among women in the U.S., with a 13% estimated risk of requiring surgery by age 80. Senolytic agents like dasatinib and quercetin (D+Q) target age-related cellular senescence and reduce senescent cell activity in various disease processes. In their paper, researchers Erryn Tappy, Haolin Shi, Jessica Pruszynski, and Maria Florian-Rodriguez from the University of Texas Southwestern Medical Center, Department of Obstetrics and Gynecology in Dallas, utilized a mouse model of pelvic organ prolapse, Fibulin-5 knockout (Fbln-5-/-) mice, to assess the ability of D+Q to prevent development of prolapse. The D+Q injections administered did not result in significant differences in prolapse development but did reduce cellular senescence markers in Fbln-5-/- mice. This suggests senolytic agents may help mitigate the role of cellular senescence in tissue dysfunction associated with prolapse. The researchers suggest that further studies are needed to determine optimal timing, dosage, and delivery of senolytics for prolapse prevention. "This study represents one of the first to evaluate the impact of senolytic agents D+Q on the clinical development of pelvic organ prolapse and expression of proteins associated with cellular senescence in a mouse model.” DOI - https://doi.org/10.18632/aging.206120 Corresponding author - Maria Florian-Rodriguez - Maria.Florian-Rodriguez@UTSouthwestern.edu Video short - https://www.youtube.com/watch?v=kTQfjhubx_4 Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206120 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, pelvic organ prolapse, cellular senescence, senolytic agents, animal model About Aging-US The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population. The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.) Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM
    Show More Show Less
    3 mins
  • Baseline Variations and Mechanical Loading-Induced Bone Formation in Mice through Proteomics

    Baseline Variations and Mechanical Loading-Induced Bone Formation in Mice through Proteomics
    Oct 17 2024
    Bone mass declines with age, and the anabolic effects of skeletal loading decrease. While much research has focused on gene transcription, how bone ages and loses its mechanoresponsiveness at the protein level remains unclear. Researchers Christopher J. Chermside-Scabbo, John T. Shuster, Petra Erdmann-Gilmore, Eric Tycksen, Qiang Zhang, R. Reid Townsend, Matthew J. Silva from Washington University School of Medicine and Washington University in St. Louis, MO, share their findings which underscore the need for complementary protein-level assays in skeletal biology research. On October 12, 2024, their research paper was published as the cover of Aging (listed by MEDLINE/PubMed as “Aging (Albany NY)” and “Aging-US” by Web of Science), Volume 16, Issue 19, entitled, “A proteomics approach to study mouse long bones: examining baseline differences and mechanical loading-induced bone formation in young-adult and old mice.” Full blog - https://aging-us.org/2024/10/exploring-baseline-variations-and-mechanical-loading-induced-bone-formation-in-young-adult-and-aging-mice-through-proteomics/ Paper DOI - https://doi.org/10.18632/aging.206131 Corresponding author - Christopher J. Chermside-Scabbo - ccherms@wustl.edu Video short - https://www.youtube.com/watch?v=xm6o7gWH8p4 Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206131 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, bone, mechanical loading, proteomics, RNA-seq/transcriptomics About Aging-US The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population. The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.) Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc Media Contact 18009220957 MEDIA@IMPACTJOURNALS.COM
    Show More Show Less
    6 mins
  • Fibroblast Growth Factor 21 and Survival in the Elderly: Polsenior2 Study Results

    Fibroblast Growth Factor 21 and Survival in the Elderly: Polsenior2 Study Results
    Oct 17 2024
    BUFFALO, NY- October 17, 2024 – A new #research paper was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science), Volume 16, Issue 19 on September 18, 2024, entitled, “Fibroblast growth factor 21 inversely correlates with survival in elderly population – the results of the Polsenior2 study.” As noted in the abstract, fibroblast growth factor 21 (FGF21) is a liver-secreted hormone involved in regulating lipid, glucose, and energy metabolism. Its serum concentration increases with age and is elevated in various diseases. FGF21 is currently being investigated for its potential as a biomarker and therapeutic target. In their paper, Polish researchers Gabriela Handzlik, Aleksander J. Owczarek, Andrzej Więcek, Małgorzata Mossakowska, Tomasz Zdrojewski, Anna Chudek, Magdalena Olszanecka-Glinianowicz, and Jerzy Chudek from the Medical University of Silesia in Katowice, the International Institute of Molecular and Cell Biology in Warsaw, and the Medical University of Gdansk aimed to assess the prognostic value of FGF21 in an older, population-based cohort from the PolSenior2 study. The researchers report that in a sub-analysis of 3,512 individuals aged 60 and older, stratified into tertiles based on FGF21 levels, the survival estimate was worse in participants with middle and high FGF21 levels compared to those in the lowest tertile. These findings were supported by univariable Cox regression analysis, where participants in the middle and high FGF21 tertiles, after adjusting for age, had a 1.43-fold (HR 1.31; 95% CI, 1.05–1.62) and 2.56-fold (HR 1.94; 95% CI, 1.59–2.37) increased risk of mortality, respectively, compared to the lowest tertile. In multivariable Cox regression analysis, the highest FGF21 levels were independently associated with increased mortality (HR 1.53; 95% CI, 1.22–1.92), regardless of co-morbidities and blood parameters. "These results indicate that higher serum FGF21 concentration is an independent predictor of all-cause mortality in the general population of older adults.” DOI - https://doi.org/10.18632/aging.206114 Corresponding author - Gabriela Handzlik - ghandzlik@sum.edu.pl Video short - https://www.youtube.com/watch?v=QkPrI68nbLE Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206114 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, fibroblast growth factor 21, survival, population-based study, longevity About Aging-US The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population. The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.) Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM
    Show More Show Less
    4 mins